<SEC-DOCUMENT>0001140361-23-020613.txt : 20230426
<SEC-HEADER>0001140361-23-020613.hdr.sgml : 20230426
<ACCEPTANCE-DATETIME>20230426163844
ACCESSION NUMBER:		0001140361-23-020613
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230426
DATE AS OF CHANGE:		20230426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		23850369

	BUSINESS ADDRESS:	
		STREET 1:		430 E. 29TH STREET
		STREET 2:		14 FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		430 E. 29TH STREET
		STREET 2:		14 FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>brhc20052030_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
      <div>
        <div>
          <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
          <font style="font-size: 14pt;">&#160;</font>
          <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
          <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
          <div>&#160;</div>
          <div>
            <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        </div>
        <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 8-K</div>
        <div><br>
           </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div style="text-align: center; font-weight: bold;"> <br>
           </div>
        <div style="text-align: center; font-weight: bold;">CURRENT REPORT</div>
        <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</div>
        <div>&#160;</div>
        <div style="text-align: center; font-weight: bold;">Date of Report (Date of earliest event reported): April 21, 2023</div>
        <div>&#160;
          <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div style="text-align: center; font-size: 24pt; font-weight: bold;"><font style="font-size: 10pt;"><font style="font-size: 24pt;">BRISTOL-MYERS SQUIBB COMPANY</font><br>
          </font> </div>
        <div style="text-align: center; font-weight: bold;">(Exact Name of Registrant as Specified in its Charter)</div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div><br>
           </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 33.33%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">Delaware<br>
                   </div>
              </td>
              <td style="width: 34%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">001-01136 <br>
                   </div>
              </td>
              <td style="width: 33.33%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">22-0790350<br>
                   </div>
              </td>
            </tr>
            <tr>
              <td style="width: 33.33%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">(State or Other Jurisdiction of Incorporation)</div>
              </td>
              <td style="width: 34%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">(Commission File Number)</div>
              </td>
              <td style="width: 33.33%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">(IRS Employer Identification Number)</div>
              </td>
            </tr>

        </table>
        <div><br>
           </div>
        <div style="text-align: center;"><font style="font-weight: bold;">430 E. 29th Street, 14th Floor</font> </div>
        <div style="text-align: center;"><font style="font-weight: bold;">New York, New York, 10016</font> </div>
        <div>
          <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Office)</div>
        </div>
        <div><br>
           </div>
        <div style="text-align: center; font-weight: bold;">Registrant&#8217;s telephone number, including area code: (212) 546-4200</div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div><br>
           </div>
        <div style="text-align: justify; text-indent: 36pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
          the following provisions (see General Instruction A.2. below):</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#9744;<br>
                 </td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#9744;<br>
                 </td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#9744;<br>
                 </td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top;">&#9744;<br>
                 </td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: center;">&#160;<font style="font-weight: bold; color: #000000;">Securities registered pursuant to Section 12(b) of the Act:</font></div>
        <div><br>
           </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 37.88%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title of each class</div>
              </td>
              <td style="width: 24.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trading Symbol(s)</div>
              </td>
              <td style="width: 37.98%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name of each exchange on which registered</div>
              </td>
            </tr>
            <tr>
              <td style="width: 37.88%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Common Stock, $0.10 Par Value<br>
                   </div>
              </td>
              <td style="width: 24.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">BMY<br>
                   </div>
              </td>
              <td style="width: 37.98%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">New York Stock Exchange<br>
                   </div>
              </td>
            </tr>
            <tr>
              <td style="width: 37.88%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">1.000% Notes due 2025<br>
                   </div>
              </td>
              <td style="width: 24.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">BMY25<br>
                   </div>
              </td>
              <td style="width: 37.98%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">New York Stock Exchange<br>
                   </div>
              </td>
            </tr>
            <tr>
              <td style="width: 37.88%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">1.750% Notes due 2035<br>
                   </div>
              </td>
              <td style="width: 24.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">BMY35<br>
                   </div>
              </td>
              <td style="width: 37.98%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">New York Stock Exchange<br>
                   </div>
              </td>
            </tr>
            <tr>
              <td style="width: 37.65%; vertical-align: top;">
                <div style="text-align: center;">Celgene Contingent Value Rights<br>
                   </div>
              </td>
              <td style="width: 24.6%; vertical-align: top;">
                <div style="text-align: center;">CELG RT<br>
                   </div>
              </td>
              <td style="width: 37.75%; vertical-align: top;">
                <div style="text-align: center;">New York Stock Exchange<br>
                   </div>
              </td>
            </tr>

        </table>
        <div>&#160;<br>
           </div>
        <div style="text-align: justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule
          12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>
        <div>&#160;</div>
        <div style="text-align: justify;">Emerging growth company &#9744;</div>
        <div>&#160;</div>
        <div style="text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
          financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
        <div>&#160;</div>
        <div>
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 5.02</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="text-align: justify;">(b)(c)&#160;&#160;&#160; On April 26, 2023, Bristol Myers Squibb Company (the
                &#8220;Company&#8221;) announced that Giovanni Caforio, M.D., the Company&#8217;s Chairman of the Board of Directors (&#8220;Board&#8221;) and Chief Executive Officer, has decided to retire as Chief Executive Officer (&#8220;CEO&#8221;) effective November 1, 2023.&#160; Dr. Caforio will
                continue to serve as Chairman of the Board until he retires as CEO on November 1, 2023, and after that will serve as&#160; Executive Chairman of the Board for a transition period to be determined by the Board.&#160; Theodore R. Samuels will continue
                to serve as Lead Independent Director.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">In addition, on April 21, 2023, the Board appointed Christopher Boerner, Ph.D., to serve as the Company&#8217;s Chief Operating Officer, effective
            April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.&#160; The Board also intends to appoint Dr. Boerner to the Board after the Annual Meeting.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">Dr. Boerner, 52, has worked for the Company since 2015 in roles of increasing seniority.&#160; He served as the Company&#8217;s Executive Vice President
            and Chief Commercialization Officer from August 2018 to April 2023.&#160; Dr. Boerner previously served as Head, International Markets from October 2017 to July 2018, and as President and Head of U.S. Commercial from February 2015 to September 2017.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">Dr. Boerner was not selected as Chief Executive Officer pursuant to any arrangement or understanding between him and any other person.&#160; There
            are no related party transactions between the Company and Dr. Boerner and there are no family relationships between Dr. Boerner and any director or executive officer of the Company.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">In connection with Dr. Boerner&#8217;s promotion to the role of Chief Operating Officer, the Compensation and Management Development Committee (the
            &#8220;Committee&#8221;) of the Board approved the following new compensation arrangements for Dr. Boerner effective April 26, 2023: (1) an increase in his annual base salary from $1,115,000 to $1,300,000 and (2) an increase in his annual target cash
            incentive opportunity from $1,115,000 to $1,560,000.&#160; &#160; Dr. Boerner&#8217;s compensation for the role of Chief Executive Officer and any other related changes in his compensation arrangements required to be disclosed on Form 8-K will be disclosed
            promptly following approval by the Committee. The Board will determine Dr. Caforio&#8217;s compensation arrangement as Executive Chairman at a later time.</div>
          <div><br>
          </div>
          <div style="text-align: justify;">A copy of the press release announcing the foregoing changes is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</div>
          <div><br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 72pt; vertical-align: top; color: #000000; font-weight: bold;">Item&#160;9.01</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Financial Statements and Exhibits.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="text-align: justify; margin-left: 9pt;">(d) Exhibits</div>
          <div><br>
          </div>
          <div style="text-align: justify;">The following exhibits are furnished as part of this Current Report on Form 8-K:</div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

              <tr>
                <td style="width: 8%; vertical-align: bottom;">&#160;</td>
                <td style="width: 2%; vertical-align: bottom;">&#160;</td>
                <td style="width: 90%; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exhibit</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">No.</div>
                </td>
                <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom;">&#160;</td>
                <td style="width: 2%; vertical-align: bottom;">&#160;</td>
                <td style="width: 90%; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom;">
                  <div style="text-align: center; color: rgb(0, 0, 0);">99.1</div>
                </td>
                <td style="width: 2%; vertical-align: bottom;">&#160;</td>
                <td style="width: 90%; vertical-align: bottom;">
                  <div>Press release of Bristol-Myers Squibb Company dated <font style="color: rgb(0, 0, 0);">April&#160;26, 2023</font>.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; color: rgb(0, 0, 0);">104</div>
                </td>
                <td style="width: 2%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter"></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            <div class="BRPFPageHeader"></div>
          </div>
          <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
          <div style="text-align: center; font-weight: bold;"> <br>
            </div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

              <tr>
                <td style="width: 8%; vertical-align: bottom;">&#160;</td>
                <td style="width: 2%; vertical-align: bottom;">&#160;</td>
                <td style="width: 90%; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exhibit</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">No.</div>
                </td>
                <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom;">&#160;</td>
                <td colspan="2" style="vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom;">
                  <div style="text-align: center; color: rgb(0, 0, 0);">99.1</div>
                </td>
                <td style="width: 2%; vertical-align: bottom;">&#160;</td>
                <td style="width: 90%; vertical-align: bottom;">
                  <div>Press release of Bristol-Myers Squibb Company dated <font style="color: rgb(0, 0, 0);">April&#160;26, 2023</font>.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; color: rgb(0, 0, 0);">104</div>
                </td>
                <td style="width: 2%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter"></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            <div class="BRPFPageHeader"></div>
          </div>
          <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 24.75pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
            its behalf by the undersigned hereunto duly authorized.&#160;</div>
          <div style="text-indent: 24.75pt;"> <br>
            </div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

              <tr>
                <td style="width: 50%; vertical-align: bottom;">&#160;</td>
                <td colspan="2" style="vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">BRISTOL-MYERS SQUIBB COMPANY</div>
                </td>
                <td style="width: 10%; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: bottom;">&#160;</td>
                <td style="width: 7%; vertical-align: bottom;">&#160;</td>
                <td style="width: 33%; vertical-align: bottom;">&#160;</td>
                <td style="width: 10%; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: bottom; padding-bottom: 2px;">
                  <div>Dated: <font style="color: rgb(0, 0, 0);">April&#160;26, 2023</font></div>
                </td>
                <td style="width: 7%; vertical-align: bottom; padding-bottom: 2px;">
                  <div style="color: rgb(0, 0, 0);">By:</div>
                </td>
                <td style="width: 33%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">/s/ Kimberly M. Jablonski</div>
                </td>
                <td style="width: 10%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: bottom;">&#160;</td>
                <td style="width: 7%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">Name:</div>
                </td>
                <td style="width: 33%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">Kimberly M. Jablonski</div>
                </td>
                <td style="width: 10%; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: bottom;">&#160;</td>
                <td style="width: 7%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">Title:</div>
                </td>
                <td style="width: 33%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">Corporate Secretary</div>
                </td>
                <td style="width: 10%; vertical-align: bottom;">&#160;</td>
              </tr>

          </table>
        </div>
        <div><br>
           </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          <div class="BRPFPageHeader"></div>
        </div>

        <div>
          <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div>
          <div style="text-align: right; font-weight: bold;">Exhibit 99.1</div>
          <div><br>
          </div>
          <div><img width="240" height="33" src="image01.jpg"></div>
          <div><br>
          </div>
          <div style="font-weight: bold;">FOR IMMEDIATE RELEASE</div>
          <div><br>
          </div>
          <div style="text-align: center; font-weight: bold;">Bristol Myers Squibb Announces Leadership Transition Plan</div>
          <div><br>
          </div>
          <div style="text-align: center; font-style: italic;">Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman
            of the Board</div>
          <div><br>
          </div>
          <div style="text-align: center; font-style: italic;">Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed
            Giovanni Caforio, MD, as CEO, Effective November 1, 2023</div>
          <div><br>
          </div>
          <div style="text-align: center; font-style: italic;">Adam Lenkowsky Appointed EVP, Chief Commercialization Officer, Effective Immediately</div>
          <div><br>
          </div>
          <div><font style="font-weight: bold;">NEW YORK &#8211; April 26, 2023 &#8211; </font>Bristol Myers Squibb (NYSE: BMY) today announced
            that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP,
            Chief Operating Officer, effective immediately, and will succeed Caforio as CEO on November 1, 2023. The Board also intends to appoint Boerner as a member of the Board after the Annual Meeting of Shareholders. Adam Lenkowsky, SVP, Head of Major
            Markets, will succeed Boerner as EVP, Chief Commercialization Officer, effective immediately. After November 1, 2023, Caforio will continue to serve as Executive Chairman for a transition period to be determined by the Board. Theodore R.
            Samuels will continue to serve as Lead Independent Director.</div>
          <div><br>
          </div>
          <div>Caforio said, &#8220;Chris is an exceptional leader, and the Board and I believe he is the right person to guide Bristol Myers Squibb through its next chapter. Chris&#8217;s
            expertise has been integral to our commercial success during his tenure at BMS. His strategic focus and passion for science, coupled with his commitment to patients make him uniquely suited for the role. I am confident the team will capitalize
            on our significant growth opportunities under Chris&#8217;s leadership.&#8221;</div>
          <div><br>
          </div>
          <div>Samuels said, &#8220;I want to thank Giovanni for his tremendous contributions to Bristol Myers Squibb. Under his leadership over the past eight years, Bristol Myers Squibb
            has nearly tripled its revenue; successfully completed our transformative combination with Celgene; overseen highly strategic acquisitions and partnerships; and launched 12 new medicines, including five first-in-class assets in five different
            disease areas. He has fostered a high-performance culture and highly engaged workforce and has been a strong advocate and champion for diversity and inclusion to drive innovation. His work has helped to solidify the foundation from which we
            will continue to build for the future.&#8221;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div>Samuels added, &#8220;Together with Giovanni, our Board of Directors has been engaged in thoughtful, ongoing succession planning and talent development discussions, and
            today&#8217;s announcement enables a smooth transition of the CEO role. Chris is an outstanding executive with profound knowledge of our company and proven ability to execute our strategy across all geographies. His expertise and leadership have been integral in the evolution of our portfolio over the past several years, notably building our leading presence in immuno-oncology, growing our CV business and
            launching multiple new medicines.&#160;He has helped build a deep bench of commercial talent as well as industry-leading market access capabilities.&#160;These efforts have been vital to helping us ensure patient access to critical medicines<font style="color: #333333;">.&#160;</font>We are confident that Chris, working together with Adam in his new role as Chief Commercialization Officer, and the rest of the leadership team, will continue
            the Bristol Myers Squibb legacy of bringing transformational medicines to patients.&#8221;</div>
          <div><br>
          </div>
          <div>Caforio continued, &#8220;As a physician, I am passionate about new medicines that can transform how serious diseases are treated &#8211; it is why my 23 years at Bristol Myers
            Squibb have been the most fulfilling of my professional career. Supported by the best people in the industry, Bristol Myers Squibb has built a rich history of innovation and pioneering new treatments and is well positioned for the future. As I
            shift my focus to spending more time with my family in Europe, I&#8217;d like to express my deepest gratitude to our talented and dedicated team for their unwavering commitment to patients.&#8221;&#160;</div>
          <div><br>
          </div>
          <div>Commenting on his appointment, Boerner said, &#8220;I am honored to serve as Bristol Myers Squibb&#8217;s next CEO. Bristol Myers Squibb is a special company, having pioneered
            many of the first generation of medicines that benefit patients across many disease areas. Today, we are poised to bring the next wave of innovative medicines to market, and my confidence in our future is stronger than ever. I look forward to
            continuing to work closely with Giovanni as we deliver for patients, shareholders and our other stakeholders.&#8221;</div>
          <div><br>
          </div>
          <div style="font-weight: bold;"><u>About Christopher Boerner, PhD</u></div>
          <div><br>
          </div>
          <div>Christopher Boerner has served as EVP, Chief Commercialization Officer since August 2018, where he has led the worldwide Commercial and Medical organizations and been
            responsible for driving growth across the company&#8217;s key franchises. Boerner previously served as head of international markets at Bristol Myers Squibb, accountable for international commercial activities. Prior to that, he served as head of
            U.S. commercial markets, responsible for U.S. sales and marketing, government affairs and market access. He joined the company in February 2015.</div>
          <div><br>
          </div>
          <div>From 2010 to 2015, Boerner served in leadership roles of increasing responsibility at Seattle Genetics, Inc. From 2002 to 2010, he served in marketing leadership
            roles at Genentech, a member of the Roche Group, focused on strategy, development and commercialization across multiple oncology products and immunology. Earlier in his career, Boerner worked for McKinsey &amp; Company, serving global
            pharmaceutical and biotechnology clients.</div>
          <div><br>
          </div>
          <div>Boerner received his PhD and MA in business administration from the Haas School of Business at the University of California, Berkeley, and holds a BA in economics and
            history from Washington University in St. Louis.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="font-weight: bold;"><u>About Bristol Myers Squibb</u></div>
          <div><br>
          </div>
          <div>Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over
            serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on&#160;<u>LinkedIn</u>,&#160;<u>Twitter</u>,&#160;<u>YouTube</u>,&#160;<u>Facebook</u>, and&#160;<u>Instagram</u><font style="font-weight: bold;">.</font></div>
          <div><br>
          </div>
          <div style="font-weight: bold;">Contacts</div>
          <div><br>
          </div>
          <div style="font-weight: bold;">Media:</div>
          <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><u>media@bms.com</u></div>
          <div><br>
          </div>
          <div style="font-weight: bold;">Investors:</div>
          <div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><u>investor.relations@bms.com</u></div>
        </div>
        <div><br>
        </div>
          <br>

        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, B8# 2(  A$! Q$!_\0
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M@NM9UIR0L9$S9Y^\X55_(_\ CM>G?"#_ )%N\_Z^S_Z"M ['H=%%% @HHHH
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M\V^$'_(S7?\ UZ'_ -"6@"Y\9/\ C^TG_KE)_-:])\.R++X:TMT.5-I%@_\
M 17FWQD_X_M)_P"N4G\UIFA>-;_P990:7K-A)/;&-9;:5&P=C#=@9X(Y]>.E
M =#T+QI(L?@S5V8@ VS+SZG@?J:XKX-1.(-8F(^1FA0'W <G_P!"%8?BOQW=
M>+XH](TVQDC@D<$IG=)*1T&!V[XYZ5Z3X&\//X<\.1VTX'VJ5C+,!V8]!^
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@XK0HH B@MX+6$16\,<,:]$C4*!^ J6BB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
